[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"grant-mrc-ukri-chemical-biological-radiological-and-nuclear-cbrn--2026-10":3,"similar-mrc-ukri-chemical-biological-radiological-and-nuclear-cbrn--2026-10":38},{"id":4,"name":5,"funder":6,"link":7,"budget":8,"budget_min_eur":9,"budget_max_eur":10,"deadline":11,"deadline_note":12,"duration":13,"trl":9,"relevance":9,"why_relevant":9,"early_career":14,"consortium":15,"first_seen":16,"last_updated":9,"update_note":9,"status":17,"stages":18,"call_frequency":19,"next_call_expected":9,"source_url":7,"created_at":20,"updated_at":21,"eligible_countries":22,"description":24,"seo_summary":25,"recurring_round":14,"canonical_id":4,"links":26},"mrc-ukri-chemical-biological-radiological-and-nuclear-cbrn--2026-10","Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures R&D","MRC (UKRI)","https:\u002F\u002Fwww.ukri.org\u002Fopportunity\u002Fexpression-of-interest-chemical-biological-radiological-and-nuclear-cbrn-medical-countermeasures-rd\u002F","Up to £4M (80% FEC)",null,4680000,"2026-10-20T00:00:00.000Z","Expression of interest deadline; full application opens 5 November 2026, closes 20 January 2027","Up to 30 months",false,"Optional — collaboration with UK industry partners and project partners encouraged but not a prerequisite for application","2026-09-13T00:00:00.000Z","open","2-stage: mandatory expression of interest → full application (by invitation)","One-off","2026-09-13T07:56:28.365Z","2026-09-13T09:43:18.673Z",[23],"GB","Funding for pre-clinical and early translational R&D of medical countermeasures for CBRN threats, from prototype development through early-phase clinical studies (up to phase 2a). Applicant must be employed by a UK-based eligible research organisation; international and commercial organisations cannot lead or partner as project lead.","{\"faq\":[{\"q\":\"How much funding does the MRC CBRN Medical Countermeasures R&D call provide?\",\"a\":\"Up to £4M per project at 80% full economic cost (FEC).\"},{\"q\":\"What is the deadline for the MRC CBRN Medical Countermeasures call?\",\"a\":\"The mandatory expression of interest is due 20 October 2026; invited full applications open 5 November 2026 and close 20 January 2027.\"},{\"q\":\"Who can lead a project for this MRC CBRN call?\",\"a\":\"Only individuals employed by a UK-based eligible research organisation can act as project lead; international and commercial organisations cannot lead or partner as lead.\"},{\"q\":\"Is a consortium required for the MRC CBRN Medical Countermeasures call?\",\"a\":\"No, collaboration with UK industry and project partners is encouraged but not required to apply.\"},{\"q\":\"What stage of research does this MRC CBRN call fund?\",\"a\":\"It funds pre-clinical and early translational R&D, from prototype development through early-phase clinical studies up to phase 2a.\"}],\"key_dates\":[\"Mandatory expression of interest due 20 October 2026\",\"Full application (by invitation only) opens 5 November 2026 and closes 20 January 2027\",\"Up to 30-month project duration\"],\"meta_description\":\"MRC CBRN Medical Countermeasures R&D call funds UK-led pre-clinical to phase 2a projects up to £4M, EOI due 20 October 2026, from MRC (UKRI).\",\"summary\":\"This MRC (UKRI) call funds pre-clinical and early translational R&D on medical countermeasures against chemical, biological, radiological and nuclear threats, covering work from prototype development through early-phase clinical studies up to phase 2a, with up to £4M per project at 80% FEC over up to 30 months. It is aimed at researchers at UK-based eligible research organisations who can act as project lead; international and commercial organisations may participate but not lead. This is a one-off call requiring a mandatory expression of interest before an invited full application stage.\",\"tags\":[\"cbrn-defence\",\"medical-countermeasures\",\"mrc\",\"ukri\",\"translational-research\",\"preclinical-research\",\"clinical-trials\",\"uk-eligibility\"],\"tips\":[\"Treat the expression of interest as a genuine gate, only invited applicants can submit a full application, so make the case for feasibility and CBRN relevance sharply at that stage.\",\"Since the project lead must sit at a UK-based eligible research organisation, structure any industry or international involvement as a partner role rather than co-lead from the outset.\",\"With up to 30 months and a scope spanning prototype to phase 2a, scope the project plan tightly to what is achievable in that window rather than proposing a full clinical development pathway.\"],\"who_should_apply\":[\"Researchers employed by a UK-based eligible research organisation able to act as project lead\",\"Teams working on pre-clinical or early translational CBRN medical countermeasures\",\"Projects spanning prototype development through early-phase clinical studies (up to phase 2a)\",\"Applicants open to involving UK industry or project partners, though not required\",\"Groups able to prepare a mandatory expression of interest ahead of an invited full application\"]}",{"matchedProgram":9,"resourceSlug":27,"relatedGuides":28,"countryHubs":29,"domainHubs":33,"closingMonth":34,"hasRelated":37,"hasBrowseRelated":37},"ukri",[],[30],{"slug":31,"demonym":32},"gb","UK researchers",[],{"slug":35,"label":36},"2026-10","October 2026",true,{"grants":39},[40,45,50,54,59],{"id":41,"name":42,"funder":6,"deadline":43,"budget":44},"mrc-proof-of-concept-2026-11","Proof of Concept","2026-11-18T00:00:00.000Z","No limit stated; 80% FEC funded",{"id":46,"name":47,"funder":6,"deadline":48,"budget":49},"mrc-ukri-mrc-proof-of-concept-2026-11","MRC Proof of Concept","2026-11-04T00:00:00.000Z","No limit stated; 80% FEC funded (100% for permitted exceptions)",{"id":51,"name":52,"funder":53,"deadline":9,"budget":9},"cancer-research-uk-drug-development-project-2026","Drug Development Project","Cancer Research UK",{"id":55,"name":56,"funder":6,"deadline":57,"budget":58},"mrc-ukri-translation-mrc-impact-acceleration-awards-2026-11","Translation MRC Impact Acceleration Awards","2026-11-11T00:00:00.000Z","£50k–£300k FEC (80% funded, i.e. up to £240k awarded)",{"id":60,"name":61,"funder":62,"deadline":63,"budget":64},"medical-research-council-mrc-mrc-experimental-medicine-2026-10","MRC Experimental Medicine","Medical Research Council (MRC)","2026-10-07T00:00:00.000Z","No limit stated; 80% of full economic cost funded"]